Of the 14 bsAb approvals since 2014, nine occurred within the last 4 years, demonstrating the rapid rise of this therapeutic class.1
This momentum shows no signs of slowing, with hundreds of candidates in clinical development for applications in oncology and beyond.
Although the majority of bsAbs thus far act as tumour antigen/T cell-coengagers, entirely novel bsAb approaches in preclinical development leverage different target combinations to expand their therapeutic possibilities.
As the field has built a foundational understanding of the diverse “building blocks” available in antibody engineering, it seems that the future of bsAb therapeutics may only be limited by our scientific creativity.
In this article, Michael Fiebig, Chief Scientific Officer at Absolute Antibody, a Vector Laboratories company, examines key innovations and considerations in the design and development of bispecific antibody therapeutics.
From understanding the breadth of our antibody engineering “toolbox” to overcoming persistent challenges in immunotherapeutic development, we’ll explore what these advancements mean for the future of oncology, autoimmune conditions, infectious diseases and more.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.